Quality in Clinical Practice

This paper reports the proceedings of the discussion panel assigned to look at clinical aspects of quality in emergency medicine. One of the seven stated objectives of the Academic Emergency Medicine consensus conference on quality in emergency medicine was to educate emergency physicians regarding quality measures and quality improvement as essential aspects of the practice of emergency medicine. Another topic of interest was a discussion of the value of information technology in facilitating quality care in the clinical practice of emergency medicine. It is important to note that this is not intended to be a comprehensive review of this extensive topic, but instead is designed to report the discussion that occurred at this session of the consensus conference.     

Progress toward re‐engineering non‐ribosomal peptide synthetase proteins: a potential new source of pharmacological agents

Many important pharmaceutical agents, including vancomycin, bleomycin, cyclosporin, and several antibiotics, are produced by non‐ribosomal peptide synthetase (NRPS) enzymes in microorganisms. The NRPS pathway produces an extensive library of products using multienzyme complexes acting in an assembly‐line fashion. Engineering an NRPS system to produce an even greater variety of products, some of which may also have beneficial therapeutic value, would be an enormous advantage. Several approaches have been successful in generating novel NRPS products: mutational biosynthesis during which nonnatural substrates are fed to an organism; domain and module swapping between different species to generate hybrid enzymes; and rational site‐directed mutagenesis, based either on phylogeny or computational prediction, intended to switch substrate specificity and produce altered products. This review will highlight the progress in these areas and describe research in the future that will extend the capacity for re‐engineering NRPS systems. Drug Dev. Res. 66:9–18, 2006. © 2006 Wiley‐Liss, Inc.     

Studying the Composition of Salmus Preparation

Salmus is a product of Salvia sclarea technology that is widely used in balneary practice. It is established that the analytical characteristics of salmus substance, as stipulated in the temporal pharmacopoeial article VFS 42-1530-85, are not objective and should not be used for evaluating the quality of the ready-to-use preparation and for monitoring the process of its manufacturing. TLC data show that salmus contains all components of sage oil (Russian State Standard GOST 3171-76) except for linalyl acetate. Qualitative specific color reactions on Silufol TLC plates showed for the first time the presence of flavonoids such as kaempferol, quercetin, juglanin, quercitrin, and rungioside and revealed one previously unknown substance, probably, of a flavonoid nature. The TLC data also showed the presence of condensed tannins and chlorophylls. It is suggested to perform quantitative analysis and identification of biologically active substances in salmus using methods for determining the content of reducing sugars (carbohydrates) and oxidizable components. New procedures for determining the sum of essential oils and flavonoids using the total content of extractable components have been developed and verified. It is suggested that these substances are among the main therapeutic components of salmus. __________ Translated from Khimiko-Farmatsevticheskii Zhurnal, Vol. 39, No. 8, pp. 33 – 36, August, 2005.